http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 28 Aug 2026 18:41:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Quoin+Pharmaceuticals%2C++++For%3A+Aug+27++Filed+by%3A+LANGER+DENNIS/26999308.html si-local-file:///var/storage/secattach/20260828/26999308.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Quoin+Pharmaceuticals%2C++++For%3A+Aug+27++Filed+by%3A+LANGER+DENNIS/26999308.html Fri, 28 Aug 2026 18:41:00 -0400 2EB0 O.49219588 QNRX http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Quoin+Pharmaceuticals%2C++++For%3A+Aug+27++Filed+by%3A+LANGER+DENNIS/26999308.html si-local-file:///var/storage/secattach/20260828/26999308.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Quoin+Pharmaceuticals%2C++++For%3A+Aug+27++Filed+by%3A+LANGER+DENNIS/26999308.html Fri, 28 Aug 2026 18:41:00 -0400 2EB0 O.49219588 QNRX http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Quoin+Pharmaceuticals%2C++++For%3A+Aug+27++Filed+by%3A+LANGER+DENNIS/26999308.html si-local-file:///var/storage/secattach/20260828/26999308.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Quoin+Pharmaceuticals%2C++++For%3A+Aug+27++Filed+by%3A+LANGER+DENNIS/26999308.html Fri, 28 Aug 2026 18:41:00 -0400 2EB0 O.49219588 QNRX http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Quoin+Pharmaceuticals%2C++++For%3A+Aug+27++Filed+by%3A+Culverwell+Anthony+James/26999304.html si-local-file:///var/storage/secattach/20260828/26999304.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Quoin+Pharmaceuticals%2C++++For%3A+Aug+27++Filed+by%3A+Culverwell+Anthony+James/26999304.html Fri, 28 Aug 2026 18:40:00 -0400 2EB0 O.49219588 QNRX http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Quoin+Pharmaceuticals%2C++++For%3A+Aug+27++Filed+by%3A+Culverwell+Anthony+James/26999304.html si-local-file:///var/storage/secattach/20260828/26999304.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Quoin+Pharmaceuticals%2C++++For%3A+Aug+27++Filed+by%3A+Culverwell+Anthony+James/26999304.html Fri, 28 Aug 2026 18:40:00 -0400 2EB0 O.49219588 QNRX http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Quoin+Pharmaceuticals%2C++++For%3A+Aug+27++Filed+by%3A+Culverwell+Anthony+James/26999304.html si-local-file:///var/storage/secattach/20260828/26999304.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Quoin+Pharmaceuticals%2C++++For%3A+Aug+27++Filed+by%3A+Culverwell+Anthony+James/26999304.html Fri, 28 Aug 2026 18:40:00 -0400 2EB0 O.49219588 QNRX http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Quoin+Pharmaceuticals%2C++++For%3A+Aug+27/26994483.html si-local-file:///var/storage/secattach/20260828/26994483.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Quoin+Pharmaceuticals%2C++++For%3A+Aug+27/26994483.html Fri, 28 Aug 2026 10:31:00 -0400 2EB0 O.49219588 QNRX http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Quoin+Pharmaceuticals%2C++++For%3A+Aug+27/26994483.html si-local-file:///var/storage/secattach/20260828/26994483.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Quoin+Pharmaceuticals%2C++++For%3A+Aug+27/26994483.html Fri, 28 Aug 2026 10:31:00 -0400 2EB0 O.49219588 QNRX http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Quoin+Pharmaceuticals%2C++++For%3A+Aug+27/26994483.html si-local-file:///var/storage/secattach/20260828/26994483.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Quoin+Pharmaceuticals%2C++++For%3A+Aug+27/26994483.html Fri, 28 Aug 2026 10:31:00 -0400 2EB0 O.49219588 QNRX http://www.streetinsider.com/Equity+Offerings/Quoin+Pharmaceuticals+raises+up+to+%2450M+in+private+placement/26992258.html <p>Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) has entered into a securities purchase agreement with healthcare-focused institutional investors to raise up to $50.0 million in gross proceeds through a private placement, according to a company statement.</p> <p>The financing includes approximately $30.8 million in upfront funding and up to an additional $19.2 million upon the potential cash exercise of accompanying ordinary warrants at the investors' election.</p> <p>Participating investors include Sirenia Capital Management LP, Sphera Healthcare, AIGH Capital Management, Nantahala Capital, StemPoint Capital LP, and Stonepine Capital Management, among others, as well as members of Quoin's management team and board of directors.</p> <p>Under the terms of the http://www.streetinsider.com/Equity+Offerings/Quoin+Pharmaceuticals+raises+up+to+%2450M+in+private+placement/26992258.html Fri, 28 Aug 2026 06:00:41 -0400 2EB0 A.36817542 A.50216923 O.25213119 O.49219588 O.57185041 QNRX http://www.streetinsider.com/Equity+Offerings/Quoin+Pharmaceuticals+raises+up+to+%2450M+in+private+placement/26992258.html <p>Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) has entered into a securities purchase agreement with healthcare-focused institutional investors to raise up to $50.0 million in gross proceeds through a private placement, according to a company statement.</p> <p>The financing includes approximately $30.8 million in upfront funding and up to an additional $19.2 million upon the potential cash exercise of accompanying ordinary warrants at the investors' election.</p> <p>Participating investors include Sirenia Capital Management LP, Sphera Healthcare, AIGH Capital Management, Nantahala Capital, StemPoint Capital LP, and Stonepine Capital Management, among others, as well as members of Quoin's management team and board of directors.</p> <p>Under the terms of the http://www.streetinsider.com/Equity+Offerings/Quoin+Pharmaceuticals+raises+up+to+%2450M+in+private+placement/26992258.html Fri, 28 Aug 2026 06:00:41 -0400 2EB0 A.36817542 A.50216923 O.25213119 O.49219588 O.57185041 QNRX http://www.streetinsider.com/Equity+Offerings/Quoin+Pharmaceuticals+raises+up+to+%2450M+in+private+placement/26992258.html <p>Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) has entered into a securities purchase agreement with healthcare-focused institutional investors to raise up to $50.0 million in gross proceeds through a private placement, according to a company statement.</p> <p>The financing includes approximately $30.8 million in upfront funding and up to an additional $19.2 million upon the potential cash exercise of accompanying ordinary warrants at the investors' election.</p> <p>Participating investors include Sirenia Capital Management LP, Sphera Healthcare, AIGH Capital Management, Nantahala Capital, StemPoint Capital LP, and Stonepine Capital Management, among others, as well as members of Quoin's management team and board of directors.</p> <p>Under the terms of the http://www.streetinsider.com/Equity+Offerings/Quoin+Pharmaceuticals+raises+up+to+%2450M+in+private+placement/26992258.html Fri, 28 Aug 2026 06:00:41 -0400 2EB0 A.36817542 A.50216923 O.25213119 O.49219588 O.57185041 QNRX http://www.streetinsider.com/Equity+Offerings/Quoin+Pharmaceuticals+raises+up+to+%2450M+in+private+placement/26992258.html <p>Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) has entered into a securities purchase agreement with healthcare-focused institutional investors to raise up to $50.0 million in gross proceeds through a private placement, according to a company statement.</p> <p>The financing includes approximately $30.8 million in upfront funding and up to an additional $19.2 million upon the potential cash exercise of accompanying ordinary warrants at the investors' election.</p> <p>Participating investors include Sirenia Capital Management LP, Sphera Healthcare, AIGH Capital Management, Nantahala Capital, StemPoint Capital LP, and Stonepine Capital Management, among others, as well as members of Quoin's management team and board of directors.</p> <p>Under the terms of the http://www.streetinsider.com/Equity+Offerings/Quoin+Pharmaceuticals+raises+up+to+%2450M+in+private+placement/26992258.html Fri, 28 Aug 2026 06:00:41 -0400 2EB0 A.36817542 A.50216923 O.25213119 O.49219588 O.57185041 QNRX http://www.streetinsider.com/Equity+Offerings/Quoin+Pharmaceuticals+raises+up+to+%2450M+in+private+placement/26992258.html <p>Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) has entered into a securities purchase agreement with healthcare-focused institutional investors to raise up to $50.0 million in gross proceeds through a private placement, according to a company statement.</p> <p>The financing includes approximately $30.8 million in upfront funding and up to an additional $19.2 million upon the potential cash exercise of accompanying ordinary warrants at the investors' election.</p> <p>Participating investors include Sirenia Capital Management LP, Sphera Healthcare, AIGH Capital Management, Nantahala Capital, StemPoint Capital LP, and Stonepine Capital Management, among others, as well as members of Quoin's management team and board of directors.</p> <p>Under the terms of the http://www.streetinsider.com/Equity+Offerings/Quoin+Pharmaceuticals+raises+up+to+%2450M+in+private+placement/26992258.html Fri, 28 Aug 2026 06:00:41 -0400 2EB0 A.36817542 A.50216923 O.25213119 O.49219588 O.57185041 QNRX http://www.streetinsider.com/Equity+Offerings/Quoin+Pharmaceuticals+raises+up+to+%2450M+in+private+placement/26992258.html <p>Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) has entered into a securities purchase agreement with healthcare-focused institutional investors to raise up to $50.0 million in gross proceeds through a private placement, according to a company statement.</p> <p>The financing includes approximately $30.8 million in upfront funding and up to an additional $19.2 million upon the potential cash exercise of accompanying ordinary warrants at the investors' election.</p> <p>Participating investors include Sirenia Capital Management LP, Sphera Healthcare, AIGH Capital Management, Nantahala Capital, StemPoint Capital LP, and Stonepine Capital Management, among others, as well as members of Quoin's management team and board of directors.</p> <p>Under the terms of the http://www.streetinsider.com/Equity+Offerings/Quoin+Pharmaceuticals+raises+up+to+%2450M+in+private+placement/26992258.html Fri, 28 Aug 2026 06:00:41 -0400 2EB0 A.36817542 A.50216923 O.25213119 O.49219588 O.57185041 QNRX http://www.streetinsider.com/Equity+Offerings/Quoin+Pharmaceuticals+raises+up+to+%2450M+in+private+placement/26992258.html <p>Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) has entered into a securities purchase agreement with healthcare-focused institutional investors to raise up to $50.0 million in gross proceeds through a private placement, according to a company statement.</p> <p>The financing includes approximately $30.8 million in upfront funding and up to an additional $19.2 million upon the potential cash exercise of accompanying ordinary warrants at the investors' election.</p> <p>Participating investors include Sirenia Capital Management LP, Sphera Healthcare, AIGH Capital Management, Nantahala Capital, StemPoint Capital LP, and Stonepine Capital Management, among others, as well as members of Quoin's management team and board of directors.</p> <p>Under the terms of the http://www.streetinsider.com/Equity+Offerings/Quoin+Pharmaceuticals+raises+up+to+%2450M+in+private+placement/26992258.html Fri, 28 Aug 2026 06:00:41 -0400 2EB0 A.36817542 A.50216923 O.25213119 O.49219588 O.57185041 QNRX http://www.streetinsider.com/FDA/Quoin+Pharmaceuticals+reports+interim+Phase+23+data+for+QRX003/26992257.html <p>Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) announced interim results from its ongoing Phase 2/3 study of QRX003 4% lotion in patients with Netherton Syndrome, a rare genetic skin disease with no currently approved treatments in the United States.</p> <p>The interim analysis covered the first six participants to complete 12 weeks of treatment. Four of the six participants, or 66.7%, achieved a 1-grade or greater improvement in Investigator Global Assessment (IGA) at week 12, meeting the pre-specified primary endpoint with statistical significance (p=0.0087 versus a pre-specified alpha of 0.0215). Two of those four participants achieved a 2-grade or greater IGA improvement.</p> <p>The key secondary http://www.streetinsider.com/FDA/Quoin+Pharmaceuticals+reports+interim+Phase+23+data+for+QRX003/26992257.html Fri, 28 Aug 2026 06:00:23 -0400 2EB0 A.06822034 A.50216923 O.20026344 O.49219588 O.57185041 QNRX http://www.streetinsider.com/FDA/Quoin+Pharmaceuticals+reports+interim+Phase+23+data+for+QRX003/26992257.html <p>Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) announced interim results from its ongoing Phase 2/3 study of QRX003 4% lotion in patients with Netherton Syndrome, a rare genetic skin disease with no currently approved treatments in the United States.</p> <p>The interim analysis covered the first six participants to complete 12 weeks of treatment. Four of the six participants, or 66.7%, achieved a 1-grade or greater improvement in Investigator Global Assessment (IGA) at week 12, meeting the pre-specified primary endpoint with statistical significance (p=0.0087 versus a pre-specified alpha of 0.0215). Two of those four participants achieved a 2-grade or greater IGA improvement.</p> <p>The key secondary http://www.streetinsider.com/FDA/Quoin+Pharmaceuticals+reports+interim+Phase+23+data+for+QRX003/26992257.html Fri, 28 Aug 2026 06:00:23 -0400 2EB0 A.06822034 A.50216923 O.20026344 O.49219588 O.57185041 QNRX http://www.streetinsider.com/FDA/Quoin+Pharmaceuticals+reports+interim+Phase+23+data+for+QRX003/26992257.html <p>Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) announced interim results from its ongoing Phase 2/3 study of QRX003 4% lotion in patients with Netherton Syndrome, a rare genetic skin disease with no currently approved treatments in the United States.</p> <p>The interim analysis covered the first six participants to complete 12 weeks of treatment. Four of the six participants, or 66.7%, achieved a 1-grade or greater improvement in Investigator Global Assessment (IGA) at week 12, meeting the pre-specified primary endpoint with statistical significance (p=0.0087 versus a pre-specified alpha of 0.0215). Two of those four participants achieved a 2-grade or greater IGA improvement.</p> <p>The key secondary http://www.streetinsider.com/FDA/Quoin+Pharmaceuticals+reports+interim+Phase+23+data+for+QRX003/26992257.html Fri, 28 Aug 2026 06:00:23 -0400 2EB0 A.06822034 A.50216923 O.20026344 O.49219588 O.57185041 QNRX http://www.streetinsider.com/FDA/Quoin+Pharmaceuticals+reports+interim+Phase+23+data+for+QRX003/26992257.html <p>Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) announced interim results from its ongoing Phase 2/3 study of QRX003 4% lotion in patients with Netherton Syndrome, a rare genetic skin disease with no currently approved treatments in the United States.</p> <p>The interim analysis covered the first six participants to complete 12 weeks of treatment. Four of the six participants, or 66.7%, achieved a 1-grade or greater improvement in Investigator Global Assessment (IGA) at week 12, meeting the pre-specified primary endpoint with statistical significance (p=0.0087 versus a pre-specified alpha of 0.0215). Two of those four participants achieved a 2-grade or greater IGA improvement.</p> <p>The key secondary http://www.streetinsider.com/FDA/Quoin+Pharmaceuticals+reports+interim+Phase+23+data+for+QRX003/26992257.html Fri, 28 Aug 2026 06:00:23 -0400 2EB0 A.06822034 A.50216923 O.20026344 O.49219588 O.57185041 QNRX http://www.streetinsider.com/FDA/Quoin+Pharmaceuticals+reports+interim+Phase+23+data+for+QRX003/26992257.html <p>Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) announced interim results from its ongoing Phase 2/3 study of QRX003 4% lotion in patients with Netherton Syndrome, a rare genetic skin disease with no currently approved treatments in the United States.</p> <p>The interim analysis covered the first six participants to complete 12 weeks of treatment. Four of the six participants, or 66.7%, achieved a 1-grade or greater improvement in Investigator Global Assessment (IGA) at week 12, meeting the pre-specified primary endpoint with statistical significance (p=0.0087 versus a pre-specified alpha of 0.0215). Two of those four participants achieved a 2-grade or greater IGA improvement.</p> <p>The key secondary http://www.streetinsider.com/FDA/Quoin+Pharmaceuticals+reports+interim+Phase+23+data+for+QRX003/26992257.html Fri, 28 Aug 2026 06:00:23 -0400 2EB0 A.06822034 A.50216923 O.20026344 O.49219588 O.57185041 QNRX http://www.streetinsider.com/FDA/Quoin+Pharmaceuticals+reports+interim+Phase+23+data+for+QRX003/26992257.html <p>Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) announced interim results from its ongoing Phase 2/3 study of QRX003 4% lotion in patients with Netherton Syndrome, a rare genetic skin disease with no currently approved treatments in the United States.</p> <p>The interim analysis covered the first six participants to complete 12 weeks of treatment. Four of the six participants, or 66.7%, achieved a 1-grade or greater improvement in Investigator Global Assessment (IGA) at week 12, meeting the pre-specified primary endpoint with statistical significance (p=0.0087 versus a pre-specified alpha of 0.0215). Two of those four participants achieved a 2-grade or greater IGA improvement.</p> <p>The key secondary http://www.streetinsider.com/FDA/Quoin+Pharmaceuticals+reports+interim+Phase+23+data+for+QRX003/26992257.html Fri, 28 Aug 2026 06:00:23 -0400 2EB0 A.06822034 A.50216923 O.20026344 O.49219588 O.57185041 QNRX http://www.streetinsider.com/FDA/Quoin+Pharmaceuticals+reports+interim+Phase+23+data+for+QRX003/26992257.html <p>Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) announced interim results from its ongoing Phase 2/3 study of QRX003 4% lotion in patients with Netherton Syndrome, a rare genetic skin disease with no currently approved treatments in the United States.</p> <p>The interim analysis covered the first six participants to complete 12 weeks of treatment. Four of the six participants, or 66.7%, achieved a 1-grade or greater improvement in Investigator Global Assessment (IGA) at week 12, meeting the pre-specified primary endpoint with statistical significance (p=0.0087 versus a pre-specified alpha of 0.0215). Two of those four participants achieved a 2-grade or greater IGA improvement.</p> <p>The key secondary http://www.streetinsider.com/FDA/Quoin+Pharmaceuticals+reports+interim+Phase+23+data+for+QRX003/26992257.html Fri, 28 Aug 2026 06:00:23 -0400 2EB0 A.06822034 A.50216923 O.20026344 O.49219588 O.57185041 QNRX http://www.streetinsider.com/Press+Releases/Quoin+Pharmaceuticals+Reports+Positive+Interim+Data+from+Ongoing+Phase+23+Study+of+QRX003+in+Netherton+Syndrome/26992253.html <ul type="disc"><li style="list-style-position:inside; margin-bottom:6pt; text-align:center;"><em>Interim Analysis of the First Six Patients to Complete 12 Weeks of Treatment Met Pre-Specified Alpha Adjusted Target for Primary Endpoint with Statistical Significance </em></li><li style="list-style-position:inside; margin-bottom:6pt; text-align:center;"><em>Four of Six (66.7%) Participants Achieved the Target 1-Grade or Greater Improvement in Investigator Global Assessment at Week 12 (p=0.0087) With Statistical Significance versus the Pre-Specified Alpha of 0.0215</em></li><li style="list-style-position:inside; margin-bottom:6pt; text-align:center;"><em>Key Secondary Endpoint of Global Impression of Change Also Achieved Statistical Significance at Week 12 (p=0.0070) Versus the Pre-Specified Alpha of 0.0215</em></li><li style="list-style-position:inside; margin-bottom:6pt; text-align:center;"><em> All Three Participants with Moderate-Severe Pruritus (Itch) at Baseline Achieved a Clinically Meaningful Outcome http://www.streetinsider.com/Press+Releases/Quoin+Pharmaceuticals+Reports+Positive+Interim+Data+from+Ongoing+Phase+23+Study+of+QRX003+in+Netherton+Syndrome/26992253.html Fri, 28 Aug 2026 06:00:00 -0400 2EB0 A.06822034 A.50216923 O.20026344 O.49219588 O.57185041 QNRX http://www.streetinsider.com/Press+Releases/Quoin+Pharmaceuticals+Reports+Positive+Interim+Data+from+Ongoing+Phase+23+Study+of+QRX003+in+Netherton+Syndrome/26992253.html <ul type="disc"><li style="list-style-position:inside; margin-bottom:6pt; text-align:center;"><em>Interim Analysis of the First Six Patients to Complete 12 Weeks of Treatment Met Pre-Specified Alpha Adjusted Target for Primary Endpoint with Statistical Significance </em></li><li style="list-style-position:inside; margin-bottom:6pt; text-align:center;"><em>Four of Six (66.7%) Participants Achieved the Target 1-Grade or Greater Improvement in Investigator Global Assessment at Week 12 (p=0.0087) With Statistical Significance versus the Pre-Specified Alpha of 0.0215</em></li><li style="list-style-position:inside; margin-bottom:6pt; text-align:center;"><em>Key Secondary Endpoint of Global Impression of Change Also Achieved Statistical Significance at Week 12 (p=0.0070) Versus the Pre-Specified Alpha of 0.0215</em></li><li style="list-style-position:inside; margin-bottom:6pt; text-align:center;"><em> All Three Participants with Moderate-Severe Pruritus (Itch) at Baseline Achieved a Clinically Meaningful Outcome http://www.streetinsider.com/Press+Releases/Quoin+Pharmaceuticals+Reports+Positive+Interim+Data+from+Ongoing+Phase+23+Study+of+QRX003+in+Netherton+Syndrome/26992253.html Fri, 28 Aug 2026 06:00:00 -0400 2EB0 A.06822034 A.50216923 O.20026344 O.49219588 O.57185041 QNRX